Ultragenyx Pharmaceutical Inc. (RARE) — 8-K Filings

8-K Filings (31)

• Ultragenyx Pharmaceutical Files 8-K — Apr 2, 2026 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on April 2, 2026, reporting other events. The filing does not contain specific financial figures or new material agr
• 8-K Filing — Dec 30, 2025
• 8-K Filing — Dec 29, 2025
• 8-K Filing — Nov 4, 2025
• Ultragenyx Pharmaceutical Inc. Files 8-K — Oct 30, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on October 30, 2025, reporting an 'Other Event'. The filing does not contain specific details about the event itself
• Ultragenyx Pharmaceutical Inc. Files 8-K — Sep 8, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on September 8, 2025, to report other events. The filing does not contain specific details about the nature of these
• Ultragenyx Pharmaceutical Inc. Files 8-K — Aug 18, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on August 18, 2025, to report other events. The filing does not contain specific details about the nature of these e
• Ultragenyx Pharmaceutical Files 8-K on Financials — Aug 5, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on August 5, 2025, reporting on its results of operations and financial condition. The filing includes financial sta
• Ultragenyx Pharmaceutical Inc. Files 8-K — Jul 31, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on July 31, 2025, reporting an "Other Event." The filing does not contain specific details about the event itself, b
• Ultragenyx Pharmaceutical Inc. Files 8-K — Jul 11, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on July 11, 2025, to report other events. The filing does not contain specific details about the nature of these eve
• Ultragenyx Pharmaceutical Inc. Files 8-K — Jul 9, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on July 9, 2025, to report other events. The filing does not contain specific details about the nature of these even
• Ultragenyx Pharmaceutical Inc. Files 8-K — Jun 27, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on June 27, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar a
• Ultragenyx Pharmaceutical Inc. Reports Director and Officer Changes — May 19, 2025 Risk: medium
  Ultragenyx Pharmaceutical Inc. filed an 8-K on May 19, 2025, reporting events that occurred on May 15, 2025. The filing indicates changes related to the departu
• Ultragenyx Pharmaceutical Files 8-K on Financials — May 6, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on May 6, 2025, reporting on its results of operations and financial condition. The filing includes financial statem
• Ultragenyx Pharmaceutical Inc. Files 8-K — Feb 13, 2025 Risk: low
  On February 13, 2025, Ultragenyx Pharmaceutical Inc. filed an 8-K report. The filing primarily concerns the company's results of operations and financial condit
• Ultragenyx Pharmaceutical Inc. Files 8-K — Jan 13, 2025 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on January 13, 2025, reporting on its results of operations and financial condition as of January 12, 2025. The fili
• Ultragenyx Pharmaceutical Inc. Files 8-K — Dec 19, 2024 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on December 19, 2024, to report other events. The filing does not contain specific details about the nature of these
• Ultragenyx Sells Woburn Facility to Catalent for $100M — Nov 12, 2024 Risk: medium
  Ultragenyx Pharmaceutical Inc. announced on November 9, 2024, that it has entered into a definitive agreement to sell its gene therapy manufacturing facility lo
• Ultragenyx Pharmaceutical Inc. Files 8-K — Nov 5, 2024 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on November 5, 2024, to report on its results of operations and financial condition, as well as to file financial st
• Ultragenyx Pharmaceutical Inc. Files 8-K — Oct 7, 2024 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on October 7, 2024, to report other events. The filing does not contain specific details about the nature of these e
• Ultragenyx Pharmaceutical Inc. Files 8-K — Oct 3, 2024 Risk: medium
  Ultragenyx Pharmaceutical Inc. filed an 8-K on October 3, 2024, to report other events. The filing does not contain specific details about the nature of these e
• Ultragenyx Pharmaceutical Files 8-K on Financials — Aug 1, 2024 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on August 1, 2024, reporting on its results of operations and financial condition. The filing includes financial sta
• Ultragenyx Sells European Crysvita Rights to Novo Nordisk for $300M — Jul 17, 2024 Risk: medium
  Ultragenyx Pharmaceutical Inc. announced on July 17, 2024, that it has entered into a definitive agreement to sell its European commercialization rights for the
• Ultragenyx Pharmaceutical Inc. Files 8-K with Officer, Director, and Compensation Updates — Jun 21, 2024 Risk: low
  On June 18, 2024, Ultragenyx Pharmaceutical Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, the appo
• Ultragenyx Pharmaceutical Inc. Files 8-K — Jun 17, 2024 Risk: medium
  On June 13, 2024, Ultragenyx Pharmaceutical Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executiv
• Ultragenyx Sells European Ops for $100M — Jun 12, 2024 Risk: medium
  Ultragenyx Pharmaceutical Inc. announced on June 11, 2024, that it has entered into a definitive agreement to sell its European commercial operations and relate
• Ultragenyx Pharmaceutical Inc. Files 8-K — May 30, 2024 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on May 30, 2024, to report other events and financial statements. The filing does not detail specific transactions o
• Ultragenyx Pharmaceutical Inc. Files 8-K — May 2, 2024 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on May 2, 2024, to report on its results of operations and financial condition. The filing includes financial statem
• Ultragenyx Pharmaceutical Inc. Files 8-K — Apr 15, 2024 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on April 15, 2024, to report other events and financial statements. The filing does not contain specific details abo
• Ultragenyx Files 8-K on Financial Results & Operations — Feb 15, 2024 Risk: low
  Ultragenyx Pharmaceutical Inc. filed an 8-K on February 15, 2024, to report on its results of operations and financial condition, along with financial statement
• Ultragenyx Files 8-K on Jan 7, Signals Upcoming Disclosure — Jan 8, 2024
  Ultragenyx Pharmaceutical Inc. filed an 8-K on January 7, 2024, indicating a current report under Section 13 or 15(d) of the Securities Exchange Act of 1934. Th

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX